GlassScriptPhysician profile
Laura Lynn Cooley
NPI 1912006479
$822.21
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.02 · 2020: $107 · 2021: $207 · 2022: $133 · 2023: $261 · 2024: $14.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $276.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $130.12 | 2019-2024 | Vaxelis, Vaxneuvance, Gardasil 9 |
| Biohaven Pharmaceuticals, INC. | $79.49 | 2021 | |
| Sanofi Pasteur INC. | $78.73 | 2019-2023 | |
| Ironshore Pharmaceuticals INC. | $73.82 | 2022-2023 | Jornay Pm |
| Astrazeneca Pharmaceuticals LP | $67.94 | 2019-2021 | |
| Ibsa Pharma INC. | $58.72 | 2022-2023 | Tirosint, Licart |
| Pfizer INC. | $57.44 | 2021-2023 | |
| Glaxosmithkline, LLC. | $53.21 | 2019-2023 | Bexsero |
| Therapeuticsmd, INC. | $48.18 | 2019-2020 | |
| Exact Sciences Corporation | $39.16 | 2023 | Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $29.60 | 2022 | |
| Adlon Therapeutics L.P. | $25.25 | 2020-2021 | |
| Sobi, INC | $19.23 | 2022 | |
| Novo Nordisk INC | $17.04 | 2023 | Rybelsus, Ozempic |
| Takeda Pharmaceuticals U.S.A., INC. | $16.61 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $13.97 | 2023 | Flucelvax Quadrivalent |
| Shire North American Group INC | $13.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Cooley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.